1. World Health Organization. WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products. 2017; https://apps.who.int/iris/handle/10665/326708.
2. Ching C, Zaman MH. Development and selection of low- level multi-drug resistance over an extended range of sub-inhibitory ciprofloxacin concentrations in Escherichia coli. Sci Rep. 2020;28:1–9.
3. Ching C, Zaman MH. Impact of ciprofloxacin impurities on bacterial growth, antibiotic resistance development and content assays. Lett Appl Microbiol. 2021;11:1–9.
4. Weinstein ZB, Zaman H. Evolution of rifampin resistance in Escherichia coli and mycobacterium smegmatis due to substandard drugs. Antimicrob Agents Chemother. 2018;14:1–8.
5. World Health Organization. A Study on the Public Health and Socieconomic Impact of Substandard and Falsified Medical Products. 2017; https://www.who.int/medicines/regulation/ssffc/publications/se-study-sf/en/.